Q32 Bio Inc.
LSE: 0T6G.L0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- London Stock Exchange
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- CEO
- Jodie Pope Morrison
- Employees
- 42
- Headquarters
- Waltham, United States
- IPO year
- 2018
- Market cap
- $68.2M
- Website
- https://www.q32bio.com
Loading 0T6G…
Loading profile data…Frequently asked questions about 0T6G
What does Q32 Bio Inc. (0T6G.L) do?
Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore comp...
Where does 0T6G.L trade?
Q32 Bio Inc. (0T6G.L) trades on the London Stock Exchange.
What sector is 0T6G.L in?
Q32 Bio Inc. (0T6G.L) operates in the Healthcare sector, specifically in the Medical - Pharmaceuticals industry.
Who is the CEO of Q32 Bio Inc.?
Jodie Pope Morrison is the chief executive officer of Q32 Bio Inc. (0T6G.L).
Where is Q32 Bio Inc. headquartered?
Q32 Bio Inc. is headquartered in United States.
Does 0T6G.L pay a dividend?
Q32 Bio Inc. (0T6G.L) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did 0T6G.L go public?
Q32 Bio Inc. (0T6G.L) completed its initial public offering in 2018.